Navigation Links
Viral protein is an effective preventative against infection

For parents, 8 million cases of acute middle ear infections every year add up to a lot of sleepless nights and trips to the pediatrician. But new research from a collaboration between Rockefeller University and St. Jude Children’s Hospital could change all that.

In the March 23 issue of PLoS Pathogens, Rockefeller’s Vincent A. Fischetti and colleagues at St. Jude show that middle ear infections in mice can be prevented by giving the mice a lysin ?a protein derived from a virus that infects bacteria. The new technology may prevent children with the flu from developing secondary ear infections and would be an attractive alternative to traditional antibiotics, to which bacteria are rapidly becoming resistant.

The bacteria that cause middle ear infections, Streptococcus pneumoniae, aren’t transmitted at school. They already reside on the mucosal membranes in the nose, waiting for their chance to strike. When a child catches the flu, or another virus that causes an upper respiratory infection, the bacteria seize the opportunity and migrate to the middle ear, causing a secondary infection. The new treatment would kill the bacteria before it had a chance to move.

"These bacteria take advantage of a viral infection by striking when our resistance is lowered," says Fischetti, head of Rockefeller’s Laboratory of Bacterial Pathogenesis and Immunology. "You should start taking an antibiotic the moment you come down with the viral infection to prevent the secondary infection, but physicians are reluctant to do this for fear of increasing resistance to antibiotics. So we’re really in a catch-22 situation."

Fischetti’s lab has done extensive research on lysins, which are proteins derived from viruses that normally infect bacteria. After a virus has infected the bacteria and replicated, it uses lysins to punch holes in the bacteria’s cell wall, killing the bacteria, in order to escape. Fischetti’s lab has studied many different lysins and found that they work even from outside the bacterial cell as well as from the inside. In addition, unlike antibiotics, which kill many of the body’s beneficial bacteria along with the disease-causing ones they target, lysins are highly specific. Each lysin will only kill a specific type of bacteria, leaving the body’s normal flora untouched.

"We knew from our previous experiments that if you treat an animal infected or colonized with pneumococci or streptococci with these lysins, you could cure or decolonize them," says Fischetti. "But I was looking for a way to see if lysins would work for secondary infections too, and John McCullers had a very nice model system."

The two researchers collaborated ?Fischetti sent McCullers, a physician at St. Jude Children’s Hospital Department of Infectious Diseases, the lysin, and McCullers tested his mice. He colonized his mice with S. pneumoniae, treated some of them with the lysin and then gave them all influenza. Eighty percent of the mice that did not receive the lysin came down with middle ear infections, but none of the mice given the lysin did. The treatment was 100 percent effective.

"It is really a no-brainer experiment," says Fischetti. "If the bacteria aren’t there, they cannot cause the secondary infection."

"Secondary bacterial infections cause much of the sickness and about 25 percent of all deaths during flu season," says McCullers. "Eliminating these secondary infections could dramatically reduce sickness and death rates."
'"/>

Source:Rockefeller University


Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
3. Viral protein influences key cell-signaling pathway
4. Viral protein helps infected T cells stick to uninfected cells
5. Viral fitness explains different resistance patterns to aids drugs
6. Viral genetic differences are possible key to HIV dementia
7. Viral hitchhiker inhibits Wolbachia bacterias ability to proliferate
8. Viral marker of human migration suspect
9. New, automated tool successfully classifies and relates proteins in unprecedented way
10. New binding target for oncogenic viral protein
11. Controversial drug shown to act on brain protein to cut alcohol use

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  Only nine percent of ... over profits, while only 16 percent believe health insurance ... today. Meanwhile, 36 percent of U.S. adults believe health ... over profits, compared to hospitals (23%). "We ... said Wendy Salomon , vice president of reputation ...
(Date:1/17/2017)... ... January 17, 2017 , ... NeoTrident, a leading ... learning and performance management systems for high-consequence industries, announced today that they have ... life sciences industry, organizations must pay much more attention to the quality of ...
(Date:1/16/2017)... --  Valentin A. Pavlov, PhD , associate investigator, and ... of The Feinstein Institute for Medical Research ... nervous system regulates the immune system, which will help ... devices to treat disease and injury. The analysis is ... The paper examines various studies which further define the ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... 2021" report to their offering. ... The biosimilars market is expected to reach ... at a CAGR of 26.3%. The global biosimilars ... application. Factors such as rising incidence of various diseases, increasing demand ...
Breaking Biology Technology: